A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Peer Review reports

Original Submission
29 Aug 2016	Submitted	Original manuscript
10 Jan 2017	Reviewed	Reviewer Report - Nick Woods
28 Feb 2017	Reviewed	Reviewer Report - Komaraiah Palle
11 May 2017	Author responded	Author comments - Zhor Senhaji Mouhri
Resubmission - Version 2
11 May 2017	Submitted	Manuscript version 2
24 May 2017	Reviewed	Reviewer Report - Nick Woods
10 Jul 2017	Author responded	Author comments - Zhor Senhaji Mouhri
Resubmission - Version 3
10 Jul 2017	Submitted	Manuscript version 3
22 Jul 2017	Author responded	Author comments - Zhor Senhaji Mouhri
Resubmission - Version 4
22 Jul 2017	Submitted	Manuscript version 4
Publishing
24 Jul 2017	Editorially accepted
11 Aug 2017	Article published	10.1186/s12885-017-3504-1

Back to article page